Evidence map›Paper›PMID 39877450›Full record

ArticleDiabetology international2025

Cost-effective analysis focused on hypoglycemia of intermittent-scanning continuous glucose monitoring in type 1 diabetes adults: a ISCHIA randomized clinical trial.

Naoki Sakane, Munehide Matsuhisa, Akio Kuroda, Junnosuke Miura, Yushi Hirota, Ken Kato, Masao Toyoda, Ryuji Kouyama, Kunichi Kouyama, Akira Shimada and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Naoki SakaneDivision of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555 Japan.ORCID 0000-0002-2625-571X
Munehide MatsuhisaDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15 Kuramotocho, Tokushima, Tokushima 770-8503 Japan.
Akio KurodaDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15 Kuramotocho, Tokushima, Tokushima 770-8503 Japan.
Junnosuke MiuraDivision of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-8666 Japan.
Yushi HirotaDivision of Diabetes and Endocrinology, The Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho Chuo-ku, Kobe, Hyogo 650-0017 Japan.
Ken KatoDiabetes Center, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, 540-0006 Japan.
Masao ToyodaDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193 Japan.
Ryuji KouyamaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Tsuchiura Kyodo General Hospital, 4-1-1 Otsuno, Tsuchiura, Ibaraki 300-0028 Japan.
Kunichi KouyamaDepartment of Diabetes and Metabolism, National Hospital Organization Hyogo-Chuo National Hospital, 1314 Ohara, Sanda, Hyogo 669-1515 Japan.
Akira ShimadaDepartment of Endocrinology and Diabetes, Saitama Medical University, 38 Morohongo Moroyama-machi, Iruma, Saitama 350-0495 Japan.
Satoshi KawashimaKanda Naika Clinic, 5-21-3 Hannancho Abeno-ku, Osaka, Osaka 545-0021 Japan.
Yuka MatobaDepartment of Diabetes, Endocrinology and Metabolism, National Hospital Organization Kokura Medical Center, 10-1 Harugaoka, Kitakyushu Kokuraminami-ku, Fukuoka, 802-0803 Japan.
Shu MeguroDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016 Japan.
Yoshiki KusunokiDepartment of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501 Japan.
Kazuyuki HidaDepartment of Diabetology and Metabolism, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Okayama Kita-ku, Okayama, 701-1192 Japan.
Tsuyoshi TanakaDepartment of Internal Medicine, National Hospital Organization Mie Chuo Medical Center, 2158-5 Hisai Myojincho, Tsu, Mie 514-1101 Japan.
Masayuki DomichiDivision of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555 Japan.
Akiko SuganumaDivision of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555 Japan.
Shota SuzukiDepartment of Social & Community Pharmacy, School of Pharmaceutical Sciences, Wakayama Medical University, 25-1 Shichiban-cho, Wakayama, Wakayama 640-8156 Japan.
Atsuhito ToneDepartment of Internal Medicine, Okayama Saiseikai General Hospital, 2-25 Kokutaicho Kita-ku, Okayama, Okayama 700-0021 Japan.
Kiminori HosodaDivision of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565 Japan.
Takashi MurataDepartment of Clinical Nutrition, National Hospital Organization Kyoto Medical Center, 1-1Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555 Japan.
ISCHIA Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to compare the economic value of intermittent-scanning continuous glucose monitoring (isCGM) with self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes (T1D). Methods: Participants were placed on either an isCGM or SMBG arm for 84 days, in a randomized, crossover setup with a 28-day washout period. Clinically relevant hypoglycemia (<54 mg/dL) and severe hypoglycemia (SH) risks were calculated by analyzing the data from isCGM. The effectiveness variable was quality-adjusted life years (QALYs), and costs included medical costs related to the SMBG device. In addition, we performed a sensitivity analysis using a tornado diagram to confirm the robustness of the results. Patients: A total of 93 Japanese T1D adults (51.4 ± 15.3 years old, male 47.3%, and HbA1c 7.3 ± 0.7%) treated with multiple daily insulin injection (MDI). Results: Compared to the SMBG arm, clinically relevant hypoglycemia and SH risks over daytime (2.7 ± 1.7 vs. 2.4 ± 1.6 times; Conclusion: The findings suggest that isCGM use for Japanese T1D adults treated with MDI is cost saving relative to SMBG.

Indexed as

Cost analysisHypoglycemiaInsulinType 1 diabetes mellitus

Identifiers

PMID39877450
PMCPMC11769919

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.